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Introduction
Budd Chiari Syndrome is a rare disease that results from the complication of venous thrombosis. 1 It is caused by obstruction of hepatic venous outflow at any level from the small hepatic veins to the junction of inferior vena cava in the right atrium. Worldwide, it occurs in 1/100,000 of the general population. 2, 3 The syndrome was first described by Budd in 1845 and in 1899, Chiari presented 13 cases of this condition. 4, 5, 6 Etiologically, Budd-Chiari Syndrome can be classified into five groups on the basis of obstructive mechanism of inferior vena cava and veno-occlusive disease, primary lesions of the main hepatic vein, and benign/malignant invasion of the hepatic veins.
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In Budd-Chiari syndrome, high blood pressure in the hepatic veins leads to hepatomegaly and ascities. The most common presentation is ascities but can range from fulminant hepatic failure to asymptomatic forms. 8, 9 Obstruction of hepatic venous outflow is mainly caused by primary intravascular thrombosis, which can occur suddenly or be repeated overtime, accompanied by some revascularization, accounting for the variable parenchymal hepatic damage and histologic presentation. Thus there is sinusoidal congestion, liver cell loss, and fibrosis, with all three predominating in the centrilobular areas. 10 Lupus anticoagulant is an antiphospholipid antibody which is found in patients with autoimmune diseases particularly Systemic Lupus Erythematosus (SLE). 11, 12 Antiphospholipid antibodies that inhibit the conversion of prothrombin to thrombin, are found in 30 to 40% of SLE patients and react with a variety of anionic phospholipids. 13, 14 The association of Budd-Chiari Syndrome with SLE has rarely been reported. 15, 16 The diagnosis of Budd-Chiari syndrome can be difficult because of the wide spectrum of presentation of the disease and the varying severity of liver damage especially when it occurs in combination with SLE. Here we describe a girl who developed Budd-Chiari Syndrome following a 2-year history of SLE.
Case Report
A 15 years old patient was diagnosed with SLE in April 2007 based on the 1982 revised criteria proposed by the American College of Rheumatology. 17 She was one of those on a regular follow-up group in the Rheumatology Department of Fatimah Memorial Hospital, Lahore, Pakistan for one-year. In January 2008, she had acute abdominal pain, fever, generalized fatigue, hurting in legs and knees, arms stiffness, gums bleeding and anemia. There was no family history of SLE. Her weight was 52 kg and the blood pressure was 120/70 mmHg. On physical examination, the liver was enlarged. An ultrasound scan revealed an abnormal pattern of the veins in the liver (Figure-1 /L suggesting thrombocytopenia and ESR done using Westergen method was 56mm/hr. The biochemical parameters including Urea12mg/dl (15-40mg/dl), Creatinine-0.6 mg/dl (0.5-1.2 mg/dl), albumin-3.5g/dl (3.2-5g/dl), and random glucose-109 mg/dl (80-120mg/dl) were almost within normal limits (Figure 2 ).
Prothrombin time (45 sec) was significantly high. Phospholipids are required for blood clotting but this patient had antiphospholipid antibodies therefore there was prolongation of in vitro clotting time. The patient was treated with an anticoagulant, warfarin (15mg daily till the daily life get resumed); for the prophylaxis of thrombosis, Plaquenil (400mg per day), Qaban and with Deltacortil (1mg/kg body weight) that contain a synthetic corticosteroid, prednisolone were administered. Finally, the patient was treated with surgical shunts; a side-to-side portacaval shunt not only decompressed the liver ascities, but also relieved ascities and removed the risk of variceal bleeding. A differential of 10mmHg or more between the portal vein and intrahepatic IVC was considered essential.
Discussion
The Budd Chiari syndrome is a known complication of venous thrombosis; its association with SLE was first reported in 1986 by Averbuch and Levo. 18 The association of this syndrome with lupus anticoagulant was reported in one patient in 1984 but the patient did not fulfill the required criteria proposed for the diagnosis of SLE. 19 Our patient satisfied the criteria proposed for the diagnosis of SLE; here the cause of hepatic vein thrombosis is the presence of lupus anticoagulant that interferes with the normal function of blood vessels causing vasculopathy and ultimately thrombosis.
The pathogenesis of thrombosis is unknown but the proposed mechanisms include direct endothelial cell injury, antigen-antibody mediated platelet activation, and inhibition of endogenous anticoagulants such as protein C. 20, 21 Previous studies have suggested that the anticoagulant reacts with a phospholipid related-antigen shared by clotting factors, platelets, cardiolipin, and other cell membranes. The reaction between antibody and the antigen could result, on the one hand, in inhibition of clotting factors and thrombocytopenia and on the other hand, in inhibition of prostacyclin production, release of procoagulant activity, and enhanced thrombosis 22, 23 Pulsed-Doppler ultrasound is diagnostically sensitivity and was considered to be the first Budd- Evidence of abnormal blood clotting in the patient required a blood thinner, warfarin, to prevent the blood clotting of small and large blood vessels. The administration of oral anticoagulant warfarin was expected to improve the prognosis for our patient. Good clinical response to oral anticoagulants illustrates the importance of testing the presence of lupus anticoagulants in such a patient but the need is to find out the pathogenesis of thrombosis. There is no permanent cure for SLE and the goal of treatment was to relieve symptoms and to protect organs by decreasing inflammation and/or the level of autoimmune activity in the patient body. Plaquenil, is one of the better tolerated anti-rheumatic drug and was given to the patient because she was at more risk for blood clots in veins and arteries Deltacortil is one of a group of medicines called steroids which are used to treat several illnesses including Lupus. In the present study, treatment with Delatcortil provided relief for inflamed areas of the body and lessens swelling.
Conclusion
Thus this conclude that the lupus patients with Budd-Chiari Syndrome should be tested for Lupus anticoagulants and anticardiolipin antibodies as Budd-Chiari Syndrome resulting from this cause may have a good response to treatment with oral anticoagulants. Secondly, the patients of Budd-Chiari syndrome especially when it occurs with SLE; it should be managed in a Pakistani center able to offer all the interventional radiologic techniques as surgical shunt and liver transplantation; because improvement or progression of the liver disease is unpredictable and worsening liver failure can occur. Currently, radiologic intervention and liver transplantation are the mainstays of treatment. Management of such patients can be difficult but management of the primary disease is as important as the secondary complication that is Budd-Chiari syndrome.
